GLP1R and diabetes mellitus: We present a case of a 62-year-old woman with clinicopathologic features consistent with FDE secondary to injections of semaglutide (Ozempic, Novo Nordisk, Bagsværd, Denmark), a glucagon-like peptide 1 (GLP-1) receptor agonist used as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus (DM).